Highline Capital Management’s Regenxbio RGNX Stock Holding History

Highline Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-180,605	Closed	-$10.3M	–	38
2019 Q1	$10.3M	Sell	180,605 -378,007	-68%	-$18.7M	0.65%	32
2018 Q4	$23.4M	Buy	558,612 +216,612	+63%	+$12.7M	1.57%	20
2018 Q3	$25.8M	Sell	342,000 -8,000	-2%	-$576K	1.19%	22
2018 Q2	$25.1M	Buy	+350,000	New	+$16.7M	0.84%	32

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Highline Capital Management's RGNX Position: Q2 2019 in Review

Highline Capital Management sold out of Regenxbio (RGNX) in Q2 2019, closing a stake of 180,605 shares — an estimated $10.3M sold.

Highline Capital Management first reported a position in RGNX in Q2 2018 and held it in 4 quarters. The position peaked at $25.8M in Q3 2018. 186 funds tracked by Wall St. Rank hold RGNX as of Q2 2019.

Highline Capital Management reported no remaining Regenxbio position as of Q2 2019 after selling out during the quarter.
Highline Capital Management sold 180,605 Regenxbio shares in Q2 2019, an estimated $10.3M.
Highline Capital Management first reported a position in Regenxbio in Q2 2018 and held it in 4 quarters.
Highline Capital Management's Regenxbio position peaked at $25.8M in Q3 2018.
186 funds tracked by Wall St. Rank held Regenxbio as of Q2 2019.

Based on Highline Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.